Fig. 1: Breast cancers with different chemotherapeutic responses exhibit conspicuously distinct cytokine profiles in their tumor microenvironment. | Oncogene

Fig. 1: Breast cancers with different chemotherapeutic responses exhibit conspicuously distinct cytokine profiles in their tumor microenvironment.

From: CCL18 signaling from tumor-associated macrophages activates fibroblasts to adopt a chemoresistance-inducing phenotype

Fig. 1

A Representative images of H&E staining and CD10/GPR77 immunofluorescent staining in serial sections of the pre-treatment breast cancer biopsies of chemosensitive (n = 3) and chemoresistant (n = 3) patients. B, C Western blotting (B) for α-SMA, FAP, CD10, and GPR77 and flow cytometric analysis (C) for CD10 and GPR77 in primary normal breast fibroblasts (NBFs) treated with pre-treatment tumor conditional medium (CM). D Cytokine arrays of pre-treatment tumor CM, squares indicate the cytokines with significant changes. E Signal intensity of indicated cytokines in the cytokine arrays and their relative fold change between the chemoresistant (n = 3) and chemosensitive tumors (n = 3) F Flow cytometric analysis for CD10 and GPR77 in NBFs treated with chemosensitive or chemoresistant tumor CM added without or with neutralizing antibodies against IL6(αIL6), IL8(αIL8) or CCL18(αCCL18). The patients with complete remission (CR) or partial remission (PR) were classified as chemosensitive, while those with stable disease (SD) or progressive disease (PD) were chemoresistant.

Back to article page